)
Visual21 Nov 2025
Data center suppliers
Ikena Oncology (IKNA) investor relations material
Ikena Oncology Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Completed a reverse recapitalization merger with Ikena Oncology, Inc. on July 25, 2025, and a $75M private placement, resulting in a new public entity focused on immunological, autoimmune, and inflammatory diseases, with $142.6M in cash and marketable securities as of September 30, 2025.
Strengthened leadership with new CEO, CSO, CTO, and independent director appointments.
Lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is the sole clinical-stage product after divestiture of non-OX40 assets, advancing in atopic dermatitis and alopecia areata.
Initiated a Phase 2b study for IMG-007 in atopic dermatitis, with topline data expected in 2027.
Financial highlights
Net loss of $24.8 million for Q3 2025, up from $3.2 million in the prior year, with $142.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
Research and development expenses were $15.6 million for Q3 2025, up 300% year-over-year, mainly due to increased stock-based compensation and clinical trial costs.
General and administrative expenses rose to $11.0 million for Q3 2025, up 568% year-over-year, reflecting higher stock-based compensation and professional services.
Net cash used in operating activities was $40.6 million for the nine months ended September 30, 2025.
Outlook and guidance
Current cash position expected to fund operations for at least the next 12 months.
Substantial additional funding will be required to advance IMG-007 and any future product candidates through development and commercialization.
Ongoing Phase 2b ADAPTIVE trial in atopic dermatitis continues with protocol amendment planned to optimize dosing and study design; topline data anticipated in 2027.
Upcoming data presentations at ISDS 2025 to highlight IMG-007's activity in alopecia areata and atopic dermatitis.
Elaborate on IMG-007's best-in-class potential
What learnings inform the ADAPTIVE study amendment?
Outline the strategic path for IMG-007 in AA
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ikena Oncology earnings date
Q4 20254 Mar, 2026
Next Ikena Oncology earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ikena Oncology is a U.S.-based biopharmaceutical company focused on developing innovative therapies targeting cancer and other immune-related diseases. The company's research centers on molecular mechanisms that drive tumor growth and immune evasion, with a focus on precision oncology and immuno-oncology approaches. Ikena’s pipeline includes treatments aimed at targeting key signaling pathways involved in cancer progression, with therapies designed to offer new options for patients with difficult-to-treat cancers. The company is headquartered in Boston, Massachusetts, and its shares are listed on NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage